Mesirow Financial Investment Management Inc. Sells 234 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Mesirow Financial Investment Management Inc. decreased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.2% in the second quarter, Holdings Channel reports. The firm owned 2,303 shares of the biopharmaceutical company’s stock after selling 234 shares during the quarter. Mesirow Financial Investment Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $1,210,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Private Trust Co. NA increased its holdings in shares of Regeneron Pharmaceuticals by 13.1% in the 1st quarter. Private Trust Co. NA now owns 164 shares of the biopharmaceutical company’s stock worth $104,000 after purchasing an additional 19 shares in the last quarter. Proficio Capital Partners LLC increased its holdings in shares of Regeneron Pharmaceuticals by 6.2% in the 1st quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company’s stock worth $207,000 after purchasing an additional 19 shares in the last quarter. Cove Private Wealth LLC increased its holdings in shares of Regeneron Pharmaceuticals by 4.5% in the 1st quarter. Cove Private Wealth LLC now owns 460 shares of the biopharmaceutical company’s stock worth $292,000 after purchasing an additional 20 shares in the last quarter. Marino Stram & Associates LLC increased its holdings in shares of Regeneron Pharmaceuticals by 5.3% in the 2nd quarter. Marino Stram & Associates LLC now owns 396 shares of the biopharmaceutical company’s stock worth $208,000 after purchasing an additional 20 shares in the last quarter. Finally, Activest Wealth Management increased its holdings in shares of Regeneron Pharmaceuticals by 110.5% in the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 21 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Guggenheim lifted their target price on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the stock a “buy” rating in a report on Wednesday. Redburn Atlantic upgraded Regeneron Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, August 14th. Wells Fargo & Company raised their price target on Regeneron Pharmaceuticals from $580.00 to $615.00 and gave the stock an “equal weight” rating in a research note on Wednesday. Rothschild & Co Redburn initiated coverage on Regeneron Pharmaceuticals in a research note on Thursday, August 14th. They issued a “buy” rating and a $890.00 price target on the stock. Finally, Bank of America raised their price target on Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the stock an “underperform” rating in a research note on Wednesday. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $802.36.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $651.80 on Friday. The company has a market capitalization of $69.08 billion, a PE ratio of 15.61, a price-to-earnings-growth ratio of 2.03 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.06. The business’s fifty day moving average is $581.80 and its 200 day moving average is $565.22. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $883.15.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, beating the consensus estimate of $9.73 by $2.10. The company had revenue of $3.75 billion for the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.Regeneron Pharmaceuticals’s quarterly revenue was up .9% compared to the same quarter last year. During the same period in the previous year, the business earned $12.46 earnings per share. Sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Thursday, November 20th will be given a dividend of $0.88 per share. The ex-dividend date is Thursday, November 20th. This represents a $3.52 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is 8.43%.

Insiders Place Their Bets

In related news, Director Christine A. Poon sold 6,500 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the transaction, the director directly owned 2,352 shares in the company, valued at approximately $1,538,843.04. The trade was a 73.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 7.02% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.